Cytodyn Inc (CYDY)

[misiu143]

As we know , without any reason know to most , FDA cut the doses of treatment of this severe/ critical patient from 4 to 2 only .

So Leronlimab was given at 0 and 7 days , and primary endpoint should be then move from 28 days to 14 , as it should be with 2 doses ,
Then SS will be met with 82% mortality benefit we had at 14 days .

But no , FDA cut the doses , but cleverly refused to move date of primary endpoint .

It is as Rockleo said ..
As to give a drug for sugar for 14 days , but do a blood sugar at 28 days .

Interesting why FDA did that with this dying patients when we all know that undertreared patients often die.

All imo

GLTA longs